Singapore Institute Of Advanced Medicine Holdings (SGX:9G2) EBIT: S$-11.90 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Singapore Institute Of Advanced Medicine Holdings EBIT?

Singapore Institute Of Advanced Medicine Holdings SGX:9G2 +3.45% EBIT is S$-11.90 Mil as of Mar. 2026. The stock has 2 warning signs investors should review.

Singapore Institute Of Advanced Medicine Holdings's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was S$-4.79 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was S$-11.90 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Singapore Institute Of Advanced Medicine Holdings's annualized ROC % for the quarter that ended in Mar. 2026 was -15.00%. Singapore Institute Of Advanced Medicine Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -16.76%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Singapore Institute Of Advanced Medicine Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -11.03%.

Singapore Institute Of Advanced Medicine Holdings  (SGX:9G2) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Singapore Institute Of Advanced Medicine Holdings's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-20.02 * ( 1 - 0% )/( (130.617 + 136.308)/ 2 )
=-20.02/133.4625
=-15.00 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=125.212 - 11.54 - ( 3.847 - max(0, 23.271 - 6.326+3.847))
=130.617

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=122.299 - 14.227 - ( 2.482 - max(0, 33.166 - 4.93+2.482))
=136.308

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Singapore Institute Of Advanced Medicine Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-19.164/( ( (115.589 + max(-9.327, 0)) + (113.114 + max(-12.044, 0)) )/ 2 )
=-19.164/( ( 115.589 + 113.114 )/ 2 )
=-19.164/114.3515
=-16.76 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.592 + 0.126 + 0.761) - (11.54 + 0 + 0.266)
=-9.327

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2.043 + 0.129 + 0.276) - (14.227 + 0 + 0.265)
=-12.044

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Singapore Institute Of Advanced Medicine Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-11.902/107.858
=-11.03 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Singapore Institute Of Advanced Medicine Holdings EBIT Related Terms

Singapore Institute Of Advanced Medicine Holdings EBIT Historical Data

* Premium members only.

The historical data trend for Singapore Institute Of Advanced Medicine Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Singapore Institute Of Advanced Medicine Holdings EBIT Chart

Singapore Institute Of Advanced Medicine Holdings Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
EBIT
-8.19 -13.28 -16.54 -25.89 -23.88

Singapore Institute Of Advanced Medicine Holdings Quarterly Data
Jun21 Jun22 Jun23 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only 0.00 -5.47 -7.11 0.00 -4.79

SGX:9G2 vs HCA, THC, DVA: EBIT Comparison

For the Medical Care Facilities subindustry, Singapore Institute Of Advanced Medicine Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Singapore Institute Of Advanced Medicine Holdings EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Singapore Institute Of Advanced Medicine Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Singapore Institute Of Advanced Medicine Holdings's EV-to-EBIT falls into.


Singapore Institute Of Advanced Medicine Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was S$-11.90 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of S$-11.90 Mil mean?
Singapore Institute Of Advanced Medicine Holdings (SGX:9G2) has a EBIT of S$-11.90 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Singapore Institute Of Advanced Medicine Holdings.
Is Singapore Institute Of Advanced Medicine Holdings' EBIT too high?
Singapore Institute Of Advanced Medicine Holdings' current EBIT is S$-11.90 Mil.
How does Singapore Institute Of Advanced Medicine Holdings' EBIT compare to HCA and THC?
Singapore Institute Of Advanced Medicine Holdings' EBIT of S$-11.90 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Singapore Institute Of Advanced Medicine Holdings. Singapore Institute Of Advanced Medicine Holdings's current EBIT is S$-11.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Singapore Institute Of Advanced Medicine Holdings stock overvalued right now?
Singapore Institute Of Advanced Medicine Holdings (SGX:9G2) has a current EBIT of S$-11.90 Mil. The current EBIT is S$-11.90 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Singapore Institute Of Advanced Medicine Holdings (SGX:9G2), the current EBIT is S$-11.90 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Singapore Institute Of Advanced Medicine Holdings Business Description

Address 1 Biopolis Drive, No. 02-01 Amnios, Singapore, SGP, 138622
Singapore Institute of Advanced Medicine Holdings Ltd is a Singapore-based healthcare service provider comprising a medical center, diagnostic imaging facility, nuclear medicine clinic, and radiation oncology service providing proton and X-ray radiotherapy. Its operating segments are: Medical Diagnostics and Treatments, Radiation Therapy and Medical Oncology Services, and Investment Holding. Medical Diagnostics and Treatments include: cancer-related diagnostics and theranostics treatments, general diagnostics and health screening, and aesthetic services. Radiation Therapy encompasses proton beam therapy, photon radiation therapy, and Medical oncology. The majority of the company's revenue comes from the Medical Diagnostics and Treatments segment.